Cure8 research brief
The study suggests Artemisia rupestris extract can reduce inflammation, repair the intestinal barrier, and shift the gut microbiota and metabolites in a mouse colitis model — pathways that are important in IBD. These mechanisms could inform future research into microbiome- and barrier-focused therapies.
Researchers in IBD and microbiome science; clinicians following preclinical therapeutic developments; patients interested in the science behind botanical or microbiome-targeting interventions (note: preclinical only).
The study used an acute 3% DSS-induced colitis model in mice to test different doses of AR and measured clinical scores, cytokines (IL-6, CXCL-1, TNF-α), MPO, intestinal permeability, histology, 16S rRNA microbiome profiles, and untargeted metabolomics.
AR-treated mice had lower pro-inflammatory cytokines and MPO, improved barrier protein expression, reduced intestinal permeability, decreases in certain putative pathogenic taxa (e.g., Erysipelatoclostridium) and increases in taxa often considered beneficial (e.g., Bacteroides, Alloprevotella, Lachnospiraceae_NK4A136_group), plus alterations in amino acid and lipid-related metabolites.
What this is not: These results are from an animal model and report mechanistic and exploratory molecular findings (microbiome and metabolomics). They do not demonstrate safety or efficacy in humans, nor do they establish dosing or clinical benefit for people with IBD.
More work including controlled human studies would be required before clinical use could be recommended.
Results are from a DSS-induced colitis mouse model and exploratory molecular analyses (16S rRNA sequencing and untargeted metabolomics). This is preclinical evidence and does not establish safety, efficacy, or dosing in humans.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Natural Science Foundation of Youth Science and Technology Elite Talent Program, Xinjiang Medical University, award XYD2024Q01; award XYD2024Q01; Research projects of universities in Xinjiang Uygur Autonomous Region, award XJEDU2025P054
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Some people with Crohn’s have ongoing GI symptoms despite little visible inflammation. This study suggests the gut microbiome—particularly sulfur-producing bacteria—may be a reason, and diet could be a potential target...
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...
Many people with Crohn’s disease continue to have symptoms even when inflammation is absent. This study suggests the gut microbiome — specifically sulfur-producing bacteria and hydrogen sulfide production — might explain...
